Table 2.

Multivariate analysis of parameters at TD and TT, including lymphodepletion and CAR T-cell infusion

	Relapse HR (95% CI)	Early relapse HR (95% CI)	Death HR (95% CI)
Parameters at TD
Age ≥65 y
Lymphoma subtypes (DLBCL, PMBL, FL)
GC/non-GC
ECOG PS ≥2		2.95 (1.03-8.45); P = .044
B symptoms	1.85 (1.01-3.41); P = .0470
Elevated LDH	2.04 (1.19-3.49); P = .00933	9.61 (1.23-75.41); P = .031
Ann Arbor stage III/IV
EN sites ≥2			4.17 (1.99-8.72); P = .000148
IPI high vs other
R-IPI poor vs other
Parameters at TT
Age >65 y
Males
ECOG PS
Ann Arbor stage III /IV
EN sites ≥2	2.50 (1.44-4.35); P = .00111	4.67 (1.55-14.11); P = .0063	3.61 (1.55-8.38); P = .00283
IPI high vs other
R-IPI poor vs other
Progressive disease at infusion
High bridging therapy
Elevated LDH
CRP	1.12 (1.07-1.17); P < .0001	1.15 (1.03-1.29); P = .016	1.12 (1.06-1.17); P < .0001
Ferritin
Albumin
Lymphocytes
Bulky mass >5 cm
TMTV41% >80.42 mL	2.18 (1.23-3.89); P = .00794	4.35 (1.32-14.37); P = .016	3.41 (1.41-8.26); P = .00651

HR, hazard ratio; OR, odds ratio.